Skip to main content
Haisco Pharmaceutical Group Co.,Ltd logo

Haisco Pharmaceutical Group Co.,Ltd — Investor Relations & Filings

Ticker · 002653 ISIN · CNE100001BC7 LEI · 300300GRLH34A8GPJ639 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,439 across all filing types
Latest filing 2022-06-20 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 002653

About Haisco Pharmaceutical Group Co.,Ltd

https://www.haisco.com

Haisco Pharmaceutical Group Co.,Ltd. focuses on the research, development, production, and commercialization of innovative drugs and high-end generic pharmaceuticals. The company maintains a specialized portfolio across therapeutic areas including anesthesia, parenteral nutrition, anti-infection, cardiovascular health, and endocrine disorders. Key products include advanced anesthetic agents and specialized nutritional injections designed for clinical use. Haisco prioritizes technological innovation through a dedicated R&D infrastructure, targeting the development of small molecule chemical drugs and complex delivery systems. Its operations emphasize high-standard manufacturing processes and the integration of clinical research to address complex medical requirements. The company aims to provide therapeutic solutions that enhance patient care through a commitment to scientific excellence and product quality.

Recent filings

Filing Released Lang Actions
委托理财制度
Governance Information Classification · 95% confidence The document is titled '海思科医药集团股份有限公司 委托理财管理制度' which translates to 'Haisco Pharmaceutical Group Co., Ltd. Entrusted Financial Management System'. It outlines internal policies and procedures for managing entrusted financial investments, including approval authorities, decision-making processes, daily management, risk control, and reporting. There is no indication that this is a financial report, audit, earnings release, or any regulatory filing. Instead, it is a governance document detailing internal rules and management practices related to entrusted financial management. Therefore, the most appropriate classification is Governance Information (CGR). The document length is 2552 characters, which is relatively short but contains substantive policy content rather than an announcement or brief notice, so it is not an RPA or RNS.
2022-06-20 Chinese
投资者关系管理制度
Governance Information Classification · 95% confidence The document is titled as an "Investor Relations Management System" for a pharmaceutical company. It outlines principles, objectives, content, communication methods, responsibilities, and work norms related to investor relations management. There are no financial statements, no fiscal period data, no regulatory filings, no voting results, no earnings data, no audit information, or any other typical financial report content. The document is a governance or procedural document related to investor relations management practices and internal company policies. It is not a report, announcement, or transcript. Therefore, the best fitting category is Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices, including investor relations management policies.
2022-06-20 Chinese
对外投资管理制度
Governance Information Classification · 95% confidence The document is titled '海思科医药集团股份有限公司 对外投资管理制度' which translates to 'Haisco Pharmaceutical Group Co., Ltd. External Investment Management System'. It outlines the company's internal policies and procedures regarding external investments, including decision-making authority, approval processes, risk management, and information disclosure requirements. The content is a governance and management policy document rather than a financial report, earnings release, or announcement. It does not contain financial statements, audit information, or regulatory filings. It is a detailed internal governance document related to investment management practices and company rules. Therefore, the most appropriate classification is Governance Information (CGR). The document length is 2908 characters, which is consistent with a policy document rather than a full report or announcement.
2022-06-20 Chinese
董事会审计委员会工作制度
Governance Information Classification · 95% confidence The document is titled as the 'Board Audit Committee Working System' of 海思科医药集团股份有限公司 (Hisun Pharmaceutical Group Co., Ltd.). It details the structure, responsibilities, and procedures of the Board's Audit Committee, including oversight of internal and external audits, financial reporting review, and internal control supervision. It is a governance-related document outlining internal rules and committee operations rather than a financial report, earnings release, or announcement. It does not contain financial statements or audit results but focuses on governance practices related to audit oversight. Therefore, it fits best under Governance Information (CGR). The document length is 3201 characters, which is consistent with a detailed governance policy document rather than a brief announcement or a full annual report.
2022-06-20 Chinese
董事、监事、高管人员持股及变动管理制度
Governance Information Classification · 95% confidence The document is titled as a management system for the holdings and changes of shares by directors, supervisors, and senior management personnel of the company. It references laws and regulations related to securities and stock trading by insiders, and details rules and restrictions on share transactions by company executives. There is no financial data, no report of financial results, no announcement of voting results, no legal proceeding update, no capital or financing update, and no mention of any meeting materials or presentations. The document is a governance-related internal regulation concerning insider shareholding and trading management. Therefore, it fits best under Governance Information (CGR). The document length is 3328 characters, which is not very short, and it contains substantive governance rules rather than a mere announcement or certification, so it is not RNS or RPA.
2022-06-20 Chinese
内幕信息知情人管理制度
Governance Information Classification · 95% confidence The document is titled as an "Insider Information Insider Management System" for a pharmaceutical company, detailing the management, confidentiality, and registration of insider information and insider persons. It includes regulatory references to Chinese securities laws and stock exchange rules, and outlines procedures for insider information handling, confidentiality obligations, and reporting to the Shenzhen Stock Exchange. The document is a policy or governance document related to insider information management rather than a financial report, earnings release, or announcement. It does not contain financial statements, earnings data, or voting results. It is not a report publication announcement or a certification. The content fits best under Governance Information (CGR) as it details internal rules and governance practices related to insider information management within the company.
2022-06-20 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.